The Pennant Group, Inc. (PNTG) Stock Price & Analysis
The Pennant Group, Inc. (PNTG) closed at USD 42.23 on Thursday, October 22, 2026, up 2.90% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 41.04; the Oct 22, 2026 session ranged USD 41.16–42.32 on volume of 191,407 shares. Market capitalization is $1.48B, with a 52-week range of USD 22.26–42.74 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PNTG.md
Key facts (PNTG)
- Last four reported quarters (through Jun 30, 2026): revenue $1.10B, net income $32.3M (2.9% margin), free cash flow $34.7M (SEC filings).
- Valuation: P/E 45.6x (avg 34.2x at the last 3 fiscal year-ends), EV/EBITDA 22.9x, net debt $182M.
- 1 of 80 tracked superinvestors hold PNTG (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 46.83 (range 44–49).
- Total return with dividends: 1Y +72.5% vs S&P 500 +14.9%; 5Y +77.9% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 0.35, revenue estimate $299M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PNTG)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $440M | $473M | $545M | $695M | $948M | $1.10B |
| Operating income | $4.7M | $12.7M | $25.2M | $38.1M | $51.9M | $62.2M |
| Net income | $2.7M | $6.6M | $13.4M | $22.6M | $29.6M | $32.3M |
| EPS (diluted) | $0.09 | $0.22 | $0.44 | $0.70 | $0.84 | — |
| Free cash flow | -$24.5M | -$5.1M | $25.0M | $30.3M | $36.3M | $34.7M |
| Operating margin | 1.1% | 2.7% | 4.6% | 5.5% | 5.5% | 5.6% |
| Net margin | 0.6% | 1.4% | 2.5% | 3.2% | 3.1% | 2.9% |
| Revenue growth | +12.5% | +7.6% | +15.1% | +27.6% | +36.3% | — |
| Cash + short-term investments | $5.2M | $2.1M | $6.1M | $24.2M | $17.0M | — |
| Total debt | $51.4M | $62.9M | $63.9M | $0K | $174M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PNTG)
P/E 45.6x · P/S 1.3x · EV/EBITDA 22.9x · EV/Sales 1.5x · P/FCF 42.5x · P/B 3.6x · FCF yield 2.35% · Earnings yield 2.19% · Net debt $182M · EV $1.66B
P/E at fiscal year-ends: Dec 2025 33.6x, Dec 2024 37.6x, Dec 2023 31.4x.
Superinvestors (SEC 13F-HR, Q2 2026) (PNTG)
1 of 80 tracked investors hold PNTG. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.04% | $21.1M | Added +32.4% |
Analysts (PNTG)
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 46.83 (low 44, high 49).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-20 | RBC Capital | Target raised | Outperform | $42 → $44 |
| 2026-08-11 | Wells Fargo | Target raised | Overweight | $45 → $46 |
| 2026-07-14 | Truist Securities | Target raised | Buy | $42 → $48 |
| 2026-07-13 | Wells Fargo | Target raised | Overweight | $41 → $45 |
Total return (dividends reinvested) (PNTG)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +72.5% | +77.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +72.8% | +12.2% |
| Volatility (annualized) | 38.1% | 51.2% |
| Max drawdown | -18.4% (May 2026→Jun 2026) | -65.0% (Nov 2021→Oct 2022) |
PNTG analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.35 | $0.34 | +2.9% | $299.5M | 7 |
| Next quarter (ends Dec 2026) | $0.37 | $0.36 | +0.8% | $303.9M | 7 |
| Current fiscal year (ends Dec 2026) | $1.40 | $1.35 | +3.5% | $1.18B | 7 |
| Next fiscal year (ends Dec 2027) | $1.59 | $1.60 | -0.7% | $1.28B | 7 |
PNTG options: expected move
Options price a move of about ±12.5% (±$5.28) by Nov 20, 2026, which includes earnings on Nov 4, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 64.4% | ±12.5% |
| Feb 19, 2027 | 119 | 40.5% | ±18.5% |
| May 21, 2027 | 210 | 38.9% | ±23.2% |
30-day implied volatility 44.3% vs 37.7% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:26 UTC)
| Price | USD 42.23 |
|---|---|
| Change | ▲ 2.90% (up) |
| Previous Close | USD 41.04 |
| Open | USD 41.3 |
| Day Range | USD 41.16 – 42.32 |
| 52-Week Range | USD 22.26 – 42.74 |
| Volume | 191,407 shares |
| Market Cap | $1.48B |
| Exchange | NMS |
Technical Analysis (PNTG)
Nexqual's technical model rates PNTG "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.63 (neutral) |
| vs SMA50 | Above (USD 39.61) |
| MACD | 0.57 (positive) |
Analyst Ratings (PNTG)
Wall Street analysts rate PNTG "Buy" based on 7 analysts, with a mean price target of USD 46.83 (range USD 44–49), per Nexqual as of October 23, 2026 at 09:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 46.83 |
| High Target | USD 49 |
| Low Target | USD 44 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (PNTG)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.35 |
| Revenue Estimate | $299.47M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.36 vs est 0.33 ▲ beat |
| 2026-03-31 | USD 0.32 vs est 0.31 ▲ beat |
| 2025-12-31 | USD 0.34 vs est 0.32 ▲ beat |
| 2025-09-30 | USD 0.3 vs est 0.29 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financials & Fundamentals (PNTG)
| Total Revenue | $1.10B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +35.80% |
| Gross Margin | +19.59% |
| Operating Margin | +6.19% |
| Profit Margin | +2.93% |
| ROE | +10.42% |
| Debt / Equity | 1.23 |
| Current Ratio | 1.21 |
| Total Cash | $15.27M |
| Total Debt | $495.55M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $34.68M (3.1% of revenue) |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financial Health Score (PNTG)
Nexqual rates The Pennant Group, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:26 UTC.
| Growth | Strong — Revenue +36% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 20%, operating 6% (last 12 months) |
| Balance Sheet | Mixed — $15M cash and investments vs $197M debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $35M (last 4 quarters to Jun 2026, SEC), slim 3.1% margin |
| Efficiency | Mixed — ROE 10%, ROA 4.5% |
Ownership (PNTG)
| Insider Ownership | +5.09% |
|---|---|
| Institutional Ownership | +96.29% |
| Shares Outstanding | 34.93M |
| Float | 33.19M |
| Short % of Float | +3.56% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Leadership (PNTG)
The Pennant Group, Inc. is led by Brent J. Guerisoli, CEO & Chairman, per Nexqual as of October 23, 2026 at 09:26 UTC.
| CEO & Chairman | Brent J. Guerisoli |
|---|---|
| President & COO | John J. Gochnour |
| Chief Financial Officer | Lynette B. Walbom |
| President of Pinnacle Senior Living LLC | Andrew Rider |
Major Backers & Investors (PNTG)
Notable institutional backers of The Pennant Group, Inc. include Van Berkom & Associates Inc., Wasatch Advisors LP, Turtle Creek Asset Management Inc., according to Nexqual as of October 23, 2026 at 09:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Van Berkom & Associates Inc. | 6.78% |
| Wasatch Advisors LP | 5.16% |
| Turtle Creek Asset Management Inc. | 4.91% |
| Paradigm Capital Management | 4.02% |
| FMR, LLC | 3.38% |
| WASATCH FUNDS TRUST-Wasatch Small Cap Growth Fund | 3.25% |
| Provident Investment Management, Inc. | 2.69% |
| Goldman Sachs | 2.55% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.47% |
| Vanguard Group | 4.24% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AGL | agilon health, inc. | USD 90.29 | ▼ 0.77% |
| NUTX | Nutex Health Inc. | USD 206.09 | ▲ 4.29% |
| CMPS | COMPASS Pathways Plc - American | USD 11.63 | ▼ 1.77% |
| SNDA | Sonida Senior Living, Inc. | USD 33.87 | ▲ 1.2% |
| USPH | U.S. Physical Therapy, Inc. | USD 88.73 | ▲ 2.84% |
| HCSG | Healthcare Services Group, Inc. | USD 24.79 | ▲ 14.19% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt